Symbiotec Profit Drops 53% as New Businesses Incur Costs Before Revenue
The steroid API leader's consolidated profit fell sharply as operating expenses and depreciation from its biotech CDMO and complex injectables ventures weighed on earnings.
Symbiotec Pharmalab's Q1 FY27 saw revenue grow 7.4% but profit plunge 53%. The drop stems from ₹35 crore in costs from new business verticals that are yet to generate sales, with revenue expected in the next 6-12 months.
Symbiotec Pharmalab’s first quarterly results after its IPO revealed a company in transition. Its steady, cash-generative API business delivered growth, but that was overshadowed by the heavy cost of building new futures in biotech and complex injectables.
The numbers tell two stories. Consolidated revenue rose 7.4% year-on-year to ₹218.15 crore. Yet profit more than halved, falling 53% to ₹14.06 crore. The net profit margin collapsed by 830 basis points to just 6.4%.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ1 FY27 | Same quarter LYQ1 FY26 |
|---|---|---|
| Revenue (₹ Cr) | 218.15YoY +7.4% | 203.17 |
| Profit (₹ Cr) | 14.06YoY -53% | 29.92 |
| Net Profit Margin | 6.4%YoY -56% | 14.7% |
Why the bottom line buckled
The profit squeeze was not a surprise to management but a planned investment. According to CNBC TV18 and other reports, the company incurred ₹23 crore in operating expenses and ₹12 crore in depreciation specifically for its new business verticals. These are the biotech contract development and manufacturing (CDMO) services and complex injectables divisions, which have significant capacity built but are not yet generating sales.
This ₹35 crore drag completely offset a robust performance in the core API unit. The standalone API business, as per the earnings call summary, saw revenue grow 6% to about ₹215 crore with EBITDA margins holding steady around 30%. The core is healthy, but the group profit is bearing the cost of future growth.
The costs that will not fall soon
Management expects these pre-revenue expenses to continue at similar levels for the next two to three quarters. The guidance, noted by outlets like ScanX Trade, is for revenue from these new engines to begin flowing in the next 6 to 12 months. The company has secured take-or-pay contracts for its CDMO capacity and is advancing partnerships for its injectable products, aiming for commercial launches in the second half of this fiscal year.
This sets up a clear timeline for investors. The current margin compression is a near-term trade-off. The payoff depends on the timely monetization of over ₹1,000 crore already invested in these new ventures. Any delay in regulatory approvals or commercial launches would prolong the earnings pressure.
Regulatory clearance removes one overhang
A positive development came just after the quarter closed. In late September, Symbiotec received a US FDA Establishment Inspection Report for its Pithampur facility with a Voluntary Action Indicated (VAI) status. As reported by Sahi.com, this successfully closes the audit with no enforcement action required, securing regulatory compliance for its core API exports to a key market.
Key Points
- Consolidated net profit fell 53% YoY to ₹14.06 crore despite a 7.4% rise in revenue, driven by ₹35 crore in costs from new, non-revenue-generating businesses.
- The core steroid API business remains stable, with ~30% EBITDA margins and 6% revenue growth, providing the cash flow to fund new ventures.
- Management expects the cost drag to persist for 2-3 more quarters, with revenue from CDMO and complex injectables starting in the next 6-12 months.
- Recent US FDA VAI status for the Pithampur plant resolves a key regulatory overhang for the core export business.
- The company is guiding for 20-25% revenue and EBITDA growth for FY27, hinging on successful commercialization of new capacities in the second half.
Hexa Perspective
The quarter lays bare Symbiotec’s strategic bet. Investors are being asked to fund current losses for future gains in higher-margin segments. The core API business, with its global leadership and steady margins, provides a solid floor, but it is not the growth story the stock is pricing in.
The next few quarters are a waiting game. The guidance for H2 FY27 monetization is now the critical benchmark. Execution on those timelines will determine if the current profit compression is a temporary setup cost or the start of a longer gestation period. The risk is a delay; the reward, if achieved, is a significant re-rating as new revenue streams kick in.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.